ClinicalTrials.gg
RecruitingNCT07327619Updated Feb 17, 2026

A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP

A Phase 3 interventional study of Meropenem and Pralurbactam and Ceftazidime-avibactam in Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-02-17.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jan 2026; still recruiting 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
420
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Pneumonia, Bacterial with a site in China — 6 open to participants now, 6 under way, 2 of them phase 3. Pneumonia, Bacterial · China.

Started
2026
with 2 others
Phase 3
5 of 10
2 open now
Registered
8th of 10
by date
Lead sponsor
1 of 10
Qilu Pharmaceutical Co., Ltd.

Among the 10 studies in Pneumonia, Bacterial with a site in China, this one is one of 3 that started in 2026, is one of 5 in phase 3, and was the 8th registered.

Pneumonia, Bacterial

153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.

Browse Pneumonia, Bacterial studies →

Open to participants now

6 of the 10 studies in Pneumonia, Bacterial with a site in China are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 18 Pneumonia, Bacterial studies recruiting now, 12 (67%) set no upper age limit and 2 (11%) stop at 75 or younger; 2 take children under 18; 1 takes healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Pneumonia, Bacterial with a site in China, or all of them as a file.
02

Study summary

This study is to evaluate the efficacy and safety of Meropenem and Pralurbactam for Injection in Subjects with HABP/VABP. The primary objective is to demonstrate non-inferiority of Meropenem and Pralurbactam to Ceftazidime and Avibactam Sodium for Injection. This study is a randomized, double-blind, active-controlled study. The total duration of the study will be approximately 32 days including screening and follow-up.

03

Conditions studied

  • Hospital-acquired Bacterial Pneumonia and Ventilator-associated Bacterial Pneumonia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1. Male or female participants ≥18 and ≤80 years of age

    2. have a diagnosis of HAP/VAP.

    3. have systemic signs and respiratory signs or symptoms of HAP/VAP.

    4. New or worsening infiltrate on chest X-ray/CT obtained within 48 hours prior to screening.

    5. The estimated survival time is at lest 28 days.

Exclusion criteria

Exclusion Criteria:

  • 1. Diagnosed or suspected CAP, Atypical pneumonias, Viral pneumonia or Chemical pneumonia.

    2. The total duration of antibiotic exposure for antibiotics whose administration begins in the 72 hours is longer than 24 hours.

    3. Acute Physiology and Chronic Health Evaluation (APACHE) II score >30.

    4. Allergic to any carbapenem, cephalosporin, penicillin, metronidazole disodium phosphate, other beta-lactam drugs or other beta-lactamase inhibitors and their auxiliary materials.

    5. Those who have a history of drug abuse or drug abuse within 6 months before screening.

    6. Those who participated in other clinical trials within 28 days before randomization and used any test drugs or medical devices.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
420 participants (estimated)

Study arms

  • Experimental
    Meropenem and Pralurbactam

    Drug: Meropenem and Pralurbactam

  • Active comparator
    Ceftazidime-avibactam

    Drug: Ceftazidime-avibactam

Interventions

  • DrugMeropenem and Pralurbactam

    Drug pages: Meropenem · Pralurbactam

    3g,q8h,120min infusion

  • DrugCeftazidime-avibactam

    2.5g,q8h,120min infusion

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Who Died Due to Any Cause Description: Due to Day 14,Proportion of Participants Who Died Due to Any Cause in mITT

    Time frame: Day 14

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2026 (actual). Primary completion is estimated for Jun 2028, 29 months after the start.

Of 15 phase 3 interventional studies under Pneumonia, Bacterial, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 45. This study's planned 29 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 26, 2025
First posted
Jan 8, 2026
StartActual
Jan 22, 2026
Primary completionEst.
Jun 2028
CompletionEst.
Oct 2028
Last update
Feb 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07327619
Responsible party
Sponsor
First posted
Jan 8, 2026
Start date
Jan 22, 2026
Primary completion
Jun 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Feb 17, 2026

Study contacts

Bin Cao, PhD
Contact
caobin_ben@163.com
010 8420 6266

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Meropenem · Pralurbactam

Start the discussion